{"nctId":"NCT01150357","briefTitle":"Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age","startDateStruct":{"date":"2010-06"},"conditions":["Hypertension"],"count":267,"armGroups":[{"label":"Low Dose Aliskiren","type":"EXPERIMENTAL","interventionNames":["Drug: Aliskiren (6.25/12.5/25 mg)"]},{"label":"Mid dose","type":"EXPERIMENTAL","interventionNames":["Drug: Aliskiren (37.5/75/150 mg)"]},{"label":"High dose","type":"EXPERIMENTAL","interventionNames":["Drug: Aliskiren (150/300/600 mg)"]}],"interventions":[{"name":"Aliskiren (6.25/12.5/25 mg)","otherNames":[]},{"name":"Aliskiren (37.5/75/150 mg)","otherNames":[]},{"name":"Aliskiren (150/300/600 mg)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented diagnosis of hypertension as defined in the NHLBI 4th Report, 2004\n* msSBP (mean of 3 measurements) must be ≥ 95th percentile for age, gender and height, at Visit 2 (randomization) measurement as defined by the NHLBI 4th Report, 2004\n\nExclusion Criteria:\n\n* Patient receiving immunosuppressant medication (e.g. cyclosporine, MMF, etc) other than oral/topical steroids, for any medical condition\n* Current diagnosis of heart failure (NYHA Class II-IV) or history of cardiomyopathy or obstructive valvular disease\n* msSBP ≥ 25% above the 95th percentile\n* Second or third degree heart block without a pacemaker\n* AST/SGOT or ALT/SGPT \\>3 times the upper limit of the reference range\n* Total bilirubin \\> 2 times the upper limit of the reference range\n* Creatinine clearance \\< 30 mL/min/1.73m² (calculated using Modified Schwartz formula to estimate glomerular filtration rate \\[GFR\\]), based on the serum creatinine concentration obtained at the screening visit)\n* WBC count \\< 3000/mm³\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Endpoint (Phase 1)","description":"Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three sSBP measurements were used as the average sitting office blood pressure for that visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.54","spread":"0.78"},{"groupId":"OG001","value":"-5.42","spread":"1.331"},{"groupId":"OG002","value":"-9.03","spread":"1.008"}]}]}]},{"type":"PRIMARY","title":"Change in Mean Sitting Systolic Blood Pressure (msSBP) From Week 4 to Endpoint (Phase 2)","description":"Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three sSBP measurements were used as the average sitting office blood pressure for that visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.53","spread":"0.947"},{"groupId":"OG001","value":"-0.64","spread":"1.256"},{"groupId":"OG002","value":"-2.59","spread":"1.119"},{"groupId":"OG003","value":"-2.9","spread":"1.481"},{"groupId":"OG004","value":"-1.97","spread":"1.071"},{"groupId":"OG005","value":"1.11","spread":"1.185"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events and Serious Adverse Events From Baseline to Week 4 (Phase 1)","description":"Adverse events (AEs) were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events and Serious Adverse Events From Week 4 to Week 8 (Phase 2)","description":"AEs were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. SAEs were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"21","spread":null},{"groupId":"OG005","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Endpoint (Phase 1)","description":"Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three sDBP measurements were used as the average sitting office blood pressure for that visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.71","spread":"0.67"},{"groupId":"OG001","value":"-4.05","spread":"1.116"},{"groupId":"OG002","value":"-6.33","spread":"0.793"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Week 4 to Endpoint (Phase 2)","description":"Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three sDBP measurements were used as the average sitting office blood pressure for that visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.27","spread":"1.025"},{"groupId":"OG001","value":"-1.08","spread":"1.012"},{"groupId":"OG002","value":"0.89","spread":"1.502"},{"groupId":"OG003","value":"1.52","spread":"1.248"},{"groupId":"OG004","value":"0.37","spread":"1.052"},{"groupId":"OG005","value":"1.51","spread":"1.009"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Arterial Pressure (MAP) at Endpoint (Phase 1)","description":"MAP was defined as the average arterial pressure during a single cardiac cycle. The MAP was measured as sum of diastolic blood pressure (DBP) and one third of difference between systolic blood pressure (SBP) and DBP i.e. MAP = DBP+1/3\\*(SBP-DBP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.65","spread":"0.613"},{"groupId":"OG001","value":"-4.51","spread":"1.064"},{"groupId":"OG002","value":"-7.23","spread":"0.711"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Arterial Pressure (MAP) From Week 4 to Endpoint (Phase 2)","description":"MAP was defined as the average arterial pressure during a single cardiac cycle. The MAP was measured as sum of DBP and one third of difference between SBP and DBP i.e. MAP = DBP+1/3\\*(SBP-DBP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.864"},{"groupId":"OG001","value":"-0.93","spread":"0.964"},{"groupId":"OG002","value":"-0.27","spread":"1.239"},{"groupId":"OG003","value":"0.05","spread":"1.14"},{"groupId":"OG004","value":"-0.41","spread":"0.885"},{"groupId":"OG005","value":"1.37","spread":"0.918"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Positive Treatment Response at Endpoint (Phase 1)","description":"Treatment responders were defined as participants with msSBP less than 95th percentile (for age, gender and height) or a 7 mmHg decrease in msSBP from the baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null},{"groupId":"OG001","value":"58.5","spread":null},{"groupId":"OG002","value":"69.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Ambulatory Systolic and Diastolic Blood Pressure (MASBP and MADBP) at Endpoint (Phase 1)","description":"Ambulatory Blood Pressure Monitoring (ABPM) was performed over a 24-hour period using an automatic ABPM device to record the blood pressure as per study defined criteria. The participants who were selected for this evaluation wore the ABPM device for 24 hours, returned to the clinic upon completion of the 24-hour monitoring period for removal of device and BP assessments. The ABPM device was pre-set to collect readings every 20 minutes. Mean hourly systolic and diastolic blood pressure were calculated for each participant at post dosing 1 - 24 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"6.48"},{"groupId":"OG001","value":"-5.9","spread":"5.8"},{"groupId":"OG002","value":"-5.8","spread":"7.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"5.33"},{"groupId":"OG001","value":"-4.4","spread":"4.41"},{"groupId":"OG002","value":"-4.9","spread":"6.05"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Ambulatory Systolic Blood Pressure (MASBP) During Day and Night at Week 4 (Phase 1)","description":"ABPM was performed over a 24-hour period using an automatic ABPM device to record the blood pressure as per study defined criteria. Day time was defined as the average of the hourly means between 6 am and 10 pm while the night time mean was the average of the hourly means between 10 pm and 6 am.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.72","spread":"1.031"},{"groupId":"OG001","value":"-6.76","spread":"1.381"},{"groupId":"OG002","value":"-6.56","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.55","spread":"1.035"},{"groupId":"OG001","value":"-4.67","spread":"1.381"},{"groupId":"OG002","value":"-4.9","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Ambulatory Blood Pressure (MABP) in Dipper Participants at Endpoint (Phase 1)","description":"ABPM was performed over a 24-hour period using an automatic ABPM device to record the blood pressure as per study defined criteria. Dippers were defined as those participants in whom there was a decrease in mean night time (6pm - 6am) ABPM more than or equal to (≥ ) 10% as compared to average daytime (6am -6pm) ABPM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"6.18"},{"groupId":"OG001","value":"-4.6","spread":"5.47"},{"groupId":"OG002","value":"-6","spread":"6.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"5.78"},{"groupId":"OG001","value":"-3.6","spread":"4.19"},{"groupId":"OG002","value":"-5.3","spread":"5.55"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Ambulatory Blood Pressure (MABP) in Non--Dipper Participants at Endpoint (Phase 1)","description":"ABPM was performed over a 24-hour period using an automatic ABPM device to record the blood pressure as per study defined criteria. Non-dippers were defined as those participants in whom there was a decrease in mean night time ABPM less than 10% as compared to average daytime ABPM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"7.21"},{"groupId":"OG001","value":"-9.3","spread":"5.54"},{"groupId":"OG002","value":"-5.2","spread":"9.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"4.05"},{"groupId":"OG001","value":"-6.7","spread":"4.45"},{"groupId":"OG002","value":"-5.2","spread":"7.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":108},"commonTop":["Headache","Upper respiratory tract infection","Oropharyngeal pain","Diarrhoea","Acute tonsillitis"]}}}